IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin's Lymphoma at 2020 ASH Annual MeetingGlobeNewsWire • 11/04/20
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s LymphomaGlobeNewsWire • 09/30/20
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery CollaborationGlobeNewsWire • 09/24/20
Jefferies Top Growth Stocks to Buy Include 4 Red-Hot Health Care Companies24/7 Wall Street • 09/15/20
IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/20
IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/20
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19GlobeNewsWire • 04/29/20
IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/27/20
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, ApoptosisGlobeNewsWire • 01/07/20